Merck Professional - Search News

News

Merck eyes $10B buyout of Verona Pharma

Merck Breathes Life Into Its Respiratory Prospects With $10B Deal to Buy Verona Pharma

Verona Pharma brings to Merck the inhaled drug Ohtuvayre, which is FDA approved as a treatment for chronic obstructive pulmonary disease.

Reuters · 2d

Merck shells out $10 billion for Verona in bid to diversify beyond ...

Merck said on Wednesday it will acquire UK-based Verona Pharma for about $10 billion, gaining a promising respiratory treatment as it faces pressure to diversify beyond its blockbuster cancer drug ...

Pharmaceutical Technology on M… · 2d

Merck agrees to acquire Verona Pharma for $10bn

The transaction will enhance Merck's cardio-pulmonary pipeline and portfolio with the addition of Ohtuvayre, an FDA-approved COPD treatment.

11hon MSN

FDA approves shot that protects dogs from fleas and ticks for 8-12 months

The U.S. Food and Drug Administration has approved Bravecto Quantum, a new shot that protects dogs six months or older ...

19hon MSN

Blockbuster long acting flea and tick treatment for dogs coming after FDA approval

A long-acting flea and tick treatment from Merck Animal Health has earned approval for dogs at least six months old from the ...

GEN7y

Merck Manual Professional | Best Science Apps

The Merck Manual – Professional Version is an excellent resource for medical professionals. The app includes an extensive list of medical topics, ranging from clinical pharmacology to ...

Wall Street Journal2d

Merck to Buy Verona Pharma in $10 Billion Deal - WSJ

Merck & Co. has struck a roughly $10 billion deal to buy Verona Pharma, bolstering its lineup with the chronic obstructive pulmonary disease treatment Ohtuvayre as it braces for the 2028 loss of ...

Results that may be inaccessible to you are currently showing.

Hide inaccessible results